



## Media release

### Invictus announces start of manufacturing ahead of US launch

**Melbourne Australia 22 October 2018:** Invictus BioPharma Ltd, the company commercialising an innovative new non-invasive and direct drug and vitamin delivery platform which avoids the use of needles, today announced the first manufacturing run of its branded nutraceutical and sports nutrition products.

Sales of these nutraceutical products to the high-growth US heart health and sports nutrition markets will generate revenues to fund clinical studies in high-value prescription medicines aimed at major human illnesses with large unmet medical needs.

These nutraceutical products are made according to quality guidelines set down by the US Food & Drug Administration (FDA) by Capstone Nutrition in Utah, a leading US nutraceutical contract manufacturer which is FDA cGMP and TGA certified.

The first manufacturing run is expected to produce 60,000 packaged servings of each of Invictus' nE1-Elite™ and nE1-Heart™ products which will be used to support their pending US commercial launch. The product samples will also help secure US distribution and start discussions with international distributors.

Invictus BioPharma Ltd Executive Chairman and CEO Dr Glenn Tong said, "After six years of research and development, the start of manufacturing is an important milestone in the development and expansion of the business. Sales of our nutraceutical products will underpin our future growth and the development of clinical studies for a number of promising prescription drug candidates."

Invictus' non-invasive drug and vitamin delivery technology has achieved promising results in pre-clinical and clinical studies. It improves the efficacy of drug therapies and vitamin supplementation by increasing the amount of a compound able to be delivered into the blood.

For more information please contact:

Dr Glenn Tong  
Invictus BioPharma Ltd.  
Tel: +61 (0) 412 193 350

Tim Allerton or Andrew Geddes  
CityPR  
Tel: +61 (0) 2 9267 4511

---

### About Invictus BioPharma Ltd.

Invictus BioPharma Ltd. is an Australian public unlisted biotechnology company developing and commercialising novel dietary supplements and prescription medicines based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, Non-Alcoholic Fatty Liver Disease (NAFLD, Non-Alcoholic SteatoHepatitis (NASH), pancreatic cancer, hyperlipidaemia, hypertension and diabetes. Invictus BioPharma owns and controls patent and other intellectual property rights for novel approaches to non-invasively delivering tocotrienols directly to the target tissues. The Company has a product development program for evidence-based nutraceuticals and a clinical development program for prescription medicines. For more information see: [www.invictusbiopharma.com](http://www.invictusbiopharma.com)